60 yr old female known SHTN came with dyspnea for 1 day and pedal edema for 1 week
"heart failure" "hypertension" management guidelines
| # | Diagnosis | Key Distinguishing Features |
|---|---|---|
| 1 | Hypertensive HF (HFpEF) | Most likely given long-standing HTN, LVH |
| 2 | HF with Reduced EF (HFrEF) | Dilated cardiomyopathy; EF <40% on echo |
| 3 | Acute Coronary Syndrome | Chest pain, dynamic ECG changes, troponin rise |
| 4 | Pulmonary embolism | Pleuritic chest pain, tachycardia, D-dimer |
| 5 | Chronic Kidney Disease with fluid overload | Elevated creatinine, uremia symptoms |
| 6 | Mitral/Aortic valve disease | Murmur on auscultation, prior rheumatic fever |
| 7 | Thyroid dysfunction (hypothyroid) | Bradycardia, myxedema facies, TSH abnormal |
| 8 | Severe anemia | Pallor, tachycardia, Hb low |
| Test | Expected Finding in HF |
|---|---|
| ECG | LVH (Sokolow-Lyon criteria), strain pattern, AF, ischemic changes |
| SpO2 | Reduced (<94%) - severity of pulmonary edema |
| Capillary blood glucose | Rule out hyperglycemic crises |
| Test | Rationale |
|---|---|
| BNP / NT-proBNP | Key biomarker - elevated in HF; BNP >100 pg/mL or NT-proBNP >300 pg/mL supports diagnosis |
| CBC | Anemia as precipitant or contributor |
| Renal function (BMP) | Baseline creatinine - essential before initiating diuretics/ACEi |
| Serum electrolytes | Hyponatremia (poor prognosis), hypokalemia (risk with diuresis) |
| LFTs | Hepatic congestion (congestive hepatopathy) |
| Thyroid function (TSH) | Hypothyroidism as cause; hyperthyroidism as precipitant |
| Troponin I/T | Rule out ACS as precipitant |
| HbA1c, fasting lipids | Comorbidity assessment |
| Urinalysis | Proteinuria (hypertensive nephropathy), casts |
| Test | Expected Finding |
|---|---|
| Chest X-ray (PA) | Cardiomegaly (CTR >0.5), upper lobe diversion, Kerley B lines, bilateral perihilar haziness ("bat-wing"), pleural effusions |
| Echocardiogram (TTE) - KEY | LVH, EF assessment (distinguishes HFpEF vs HFrEF), diastolic dysfunction grading (E/A ratio, E/e'), wall motion abnormalities, valve lesions, pericardial effusion |
| Drug Class | Agent | Indication |
|---|---|---|
| Loop diuretic | Furosemide 40-80 mg OD/BD PO | Decongestion - cornerstone |
| ACE inhibitor | Enalapril 2.5 mg BD → titrate to 10-20 mg BD | LVSDF, reduces remodeling, mortality benefit |
| Beta-blocker | Carvedilol 3.125 mg BD / Bisoprolol 1.25 mg OD | After stabilization (avoid in acute decompensation); BP + rate control |
| MRA | Spironolactone 25-50 mg OD | EF <35%, reduces mortality |
If HFpEF (preserved EF): management is primarily diuretics for symptom relief + aggressive BP control (<130/80 mmHg), + SGLT2 inhibitor (Dapagliflozin - now evidence-based for HFpEF too).
| Class | Description |
|---|---|
| I | No symptoms with ordinary activity |
| II | Slight limitation - comfortable at rest |
| III | Marked limitation - comfortable only at rest |
| IV | Unable to carry out any activity without discomfort; symptoms at rest |
Sources: Goldman-Cecil Medicine (9780323930345), Fuster and Hurst's The Heart 15th Ed. (9781264257560), Tintinalli's Emergency Medicine (9781260019933). Dosing tables from Goldman-Cecil Medicine, p. 3077-3083.